Back to test list


Also known as: MDM2 amplification

Test category:

Oncology - Sarcoma

Use of test


The MDM2 oncogene is located on the long arm of Chromosome 12. Overexpression of this gene occurs in many types of cancer.

The overall frequency of MDM2 amplification in human tumours is 7%. The highest frequency is observed in soft tissue tumours (20%), osteosarcomas (16%) and oesophageal carcinomas (13%). This test has diagnostic implications.


In cases of unclear diagnosis, the presence of MDM2 gene amplification can be of assistance in distinguishing between (i) lipomas and atypical lipomatous tumour/well-differentiated liposarcomas, (ii) malignant undifferentiated tumours and dedifferentiated liposarcomas, and (iii) a variety of benign tumours and liposarcomas.

Ethical considerations:

This is an assay for non-heritable mutations. It does not raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.


Fluorescent in situ hybridisation (FISH) analysis, using probes to the MDM2 gene.

Requesting the test


This test is usually requested by an oncologist.

Request form:

Download the solid tumour somatic mutation request form.

Sample required:

Formalin-fixed, paraffin embedded tissue (FFPE) - 15 sections of 4 uM thickness, dried overnight at 37°C onto charged/coated slides.

Special instructions:

Please stain the first section with H&E, and label each slide with patient and block identifiers. Label the unstained sections sequentially (slides 2-15). The request should be accompanied by the somatic mutation request form (above)and a copy of the original histopathology report.

Turnaround time:

5 business days.


Up to $410.

If more information is required, the requesting clinician can call our laboratory on (07) 3377 8573.


This test is not rebated by Medicare. The laboratory assumes that the patient or client has provided informed financial consent for the test.

Click here for our billing policy.